ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 993

An Analysis Of Healthcare Resource Utilization Among Patients Undergoing Total Knee Arthroplasty In The United Kingdom

Mireia Raluy1, Michael Schoenfeld2, Dimitra Lambrelli1, Meng Wang3, Ning Wu4, Shih-Yin Chen4 and Russel Burge2, 1Health Economics, United BioSource Corporation, London, United Kingdom, 2Global Health Outcomes, Eli Lilly and Company, Indianapolis, IN, 3Economic Analysis and Solutions, United BioSource Corporation, London, United Kingdom, 4Economic Analysis and Solutions, United BioSource Corporation, Lexington, MA

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Arthroplasty, Economics, healthcare management and osteoarthritis, Knee

  • Tweet
  • Email
  • Print
Session Information

Title: Epidemiology and Health Services II & III

Session Type: Abstract Submissions (ACR)

Background/Purpose: Elective total knee arthroplasty (eTkA) is among the most commonly performed surgical procedures. The typical reasons for eTkA are pain and decreased quality of life (QoL) from osteoarthritis.  These patients can be at risk of various clinical complications, mobility impairment, muscle weakness, decreased ability to perform daily activities. The purpose of this study was to assess the patient characteristics, healthcare resource use, and costs among eTkA patients in large UK-based general practitioner and hospital databases.

Methods: The Clinical Practice Research Datalink (CPRD) linked to the Hospital Episode Statistics (HES) was used to estimate resource use in adult eTkA patients. Inclusion criteria: patients had no GP visits or inpatient stays with OPCS (4.6) procedure codes suggesting eTkA (W-40, 41, 42) in 7 days to 1 year prior to index date (hospital stay for eTkA) with at least 1 year of computerized data pre- and post-index hospitalization.  Elective TKA related medical costs (British Pound Sterling, 2012) were calculated by multiplying resource units by official publicly available costs from the NHS perspective.

Results: This study included 12,737 patients with mean age of 71 years, of whom approximately 26% were within 18–65 years of age. Pre-index, opioids (53%), NSAIDs (48%), and acetaminophen (34%) were the most common medications, followed by oral steroids (24%) and antidepressants (17%).   Nearly all patients had osteoarthritis (98.6%). Other common comorbidities were pulmonary disease (22.4%), cancer (14%), renal disease (13.9%), and osteoporosis (6.8%). The Charlson Comorbidity Index (mean score was 1.3. For the index hospitalization, average length of stay was 6.2 days and average costs (standard deviation [SD]) were £5,397 (2,459). After index hospitalization the majority of patients (97.5%) were discharged to their place of residence and 1.6% were discharged to another NHS hospital.  During their index hospitalization the majority of patients (98.0%) were treated by trauma and orthopedics; almost one-fourth (23.8%) were treated by general medicine. The mean (SD) total healthcare cost in the pre-index period was £2,507 (4168), driven mainly by inpatient costs that were £1,858. Average outpatient costs were £592 and pre-index pharmacy costs were £57.  During the post-index follow up, mean (SD) overall cost was £2068 (6519), with average inpatient costs of £1,526.

Conclusion:  This study described resource utilization, pain medications usage, and costs among patients undergoing eTkA in the UK. These estimates may provide a better understanding of the ubiquitous economic burden of this condition.


Disclosure:

M. Raluy,

Eli Lilly and Company,

2;

M. Schoenfeld,

Eli Lilly and Company,

1,

Eli Lilly and Company,

3,

Eli Lilly and Company,

9;

D. Lambrelli,

Eli Lilly and Company,

2;

M. Wang,

Eli Lilly and Company,

2;

N. Wu,

Eli Lilly and Company,

2;

S. Y. Chen,

Eli Lilly and Company,

2;

R. Burge,

Eli Lilly and Company,

3,

Eli Lilly and Company,

1.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/an-analysis-of-healthcare-resource-utilization-among-patients-undergoing-total-knee-arthroplasty-in-the-united-kingdom/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology